Octagon Capital Advisors as of March 31, 2024
Portfolio Holdings for Octagon Capital Advisors
Octagon Capital Advisors holds 56 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Apellis Pharmaceuticals Call Option (APLS) | 21.2 | $177M | 3.0M | 58.78 | |
| Alpine Immune Sciences | 5.9 | $49M | 1.2M | 39.64 | |
| Dianthus Therapeutics (DNTH) | 5.0 | $41M | 1.4M | 30.00 | |
| Verona Pharma Sponsored Ads (VRNA) | 4.6 | $38M | 2.4M | 16.09 | |
| Dyne Therapeutics (DYN) | 4.2 | $35M | 1.2M | 28.39 | |
| Arrivent Biopharma (AVBP) | 4.2 | $35M | 1.9M | 17.86 | |
| Insmed Com Par $.01 (INSM) | 3.7 | $31M | 1.1M | 27.13 | |
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 2.8 | $23M | 2.1M | 11.30 | |
| Eyepoint Pharmaceuticals Com New (EYPT) | 2.7 | $23M | 1.1M | 20.67 | |
| Ocular Therapeutix (OCUL) | 2.6 | $22M | 2.4M | 9.10 | |
| Structure Therapeutics Sponsored Ads (GPCR) | 2.6 | $22M | 507k | 42.86 | |
| Bridgebio Pharma (BBIO) | 2.6 | $21M | 690k | 30.92 | |
| Mind Medicine Mindmed Com New (MNMD) | 2.4 | $20M | 2.2M | 9.40 | |
| IsoRay | 2.1 | $18M | 15M | 1.19 | |
| Corbus Pharmaceuticals Hldgs Com New (CRBP) | 1.9 | $16M | 405k | 39.24 | |
| Praxis Precision Medicines I Com New (PRAX) | 1.9 | $16M | 260k | 61.02 | |
| Tenaya Therapeutics (TNYA) | 1.8 | $15M | 2.9M | 5.23 | |
| Jasper Therapeutics Com New (JSPR) | 1.8 | $15M | 501k | 29.36 | |
| Annexon (ANNX) | 1.8 | $15M | 2.1M | 7.17 | |
| Cytokinetics Com New (CYTK) | 1.6 | $14M | 194k | 70.11 | |
| Aerovate Therapeutics (AVTE) | 1.4 | $12M | 404k | 29.57 | |
| Miragen Therapeutics (VRDN) | 1.3 | $11M | 620k | 17.51 | |
| Gossamer Bio (GOSS) | 1.3 | $11M | 9.2M | 1.18 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.2 | $9.6M | 408k | 23.65 | |
| Glycomimetics (GLYC) | 1.1 | $9.0M | 3.0M | 3.00 | |
| Immunovant (IMVT) | 1.1 | $8.8M | 273k | 32.31 | |
| Taysha Gene Therapies Com Shs (TSHA) | 1.0 | $8.7M | 3.0M | 2.87 | |
| Akero Therapeutics (AKRO) | 1.0 | $8.6M | 340k | 25.26 | |
| Ventyx Biosciences (VTYX) | 1.0 | $8.3M | 1.5M | 5.50 | |
| Cybin Ord (CYBN) | 0.9 | $7.7M | 19M | 0.41 | |
| Arrowhead Pharmaceuticals (ARWR) | 0.9 | $7.2M | 250k | 28.60 | |
| Mineralys Therapeutics (MLYS) | 0.9 | $7.1M | 550k | 12.91 | |
| Silence Therapeutics Ads (SLN) | 0.8 | $6.8M | 315k | 21.60 | |
| Pepgen (PEPG) | 0.7 | $5.5M | 376k | 14.70 | |
| Vincerx Pharma Com New (VINC) | 0.6 | $5.1M | 1.0M | 5.06 | |
| Nuvation Bio Com Cl A (NUVB) | 0.6 | $5.0M | 1.4M | 3.64 | |
| Phathom Pharmaceuticals (PHAT) | 0.6 | $4.8M | 455k | 10.62 | |
| Mersana Therapeutics (MRSN) | 0.5 | $4.5M | 1.0M | 4.48 | |
| Terns Pharmaceuticals (TERN) | 0.5 | $4.1M | 625k | 6.56 | |
| Fate Therapeutics (FATE) | 0.5 | $3.8M | 521k | 7.34 | |
| Reneo Pharmaceuticals (RPHM) | 0.4 | $3.7M | 2.3M | 1.66 | |
| Anaptysbio Inc Common (ANAB) | 0.4 | $3.7M | 165k | 22.52 | |
| Sana Biotechnology (SANA) | 0.4 | $3.6M | 361k | 10.00 | |
| An2 Therapeutics (ANTX) | 0.4 | $3.6M | 1.1M | 3.25 | |
| Allogene Therapeutics (ALLO) | 0.4 | $3.2M | 720k | 4.47 | |
| Allovir (ALVR) | 0.4 | $3.2M | 4.2M | 0.75 | |
| Female Health (VERU) | 0.3 | $2.7M | 3.8M | 0.70 | |
| Rapt Therapeutics (RAPT) | 0.3 | $2.6M | 292k | 8.98 | |
| Nkarta (NKTX) | 0.3 | $2.6M | 240k | 10.81 | |
| Helix Acquisition Corp Ii Cl A Ord Shs (HLXB) | 0.3 | $2.6M | 250k | 10.35 | |
| Poseida Therapeutics I (PSTX) | 0.3 | $2.3M | 736k | 3.19 | |
| Century Therapeutics (IPSC) | 0.3 | $2.3M | 540k | 4.18 | |
| Adicet Bio (ACET) | 0.2 | $1.8M | 768k | 2.35 | |
| Atyr Pharma Com New (ATYR) | 0.2 | $1.4M | 700k | 1.95 | |
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $1.1M | 176k | 6.38 | |
| Cabaletta Bio (CABA) | 0.1 | $887k | 52k | 17.06 |
